Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors With MTAP Deficiency

NCT06922357 is registered in ClinicalTrials.gov with Shandong Suncadia Medicine Co., Ltd. as lead sponsor.

NCT NCT06922357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors With MTAP Deficiency
Lead sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 24, 2025
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors